| Title |
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, September 2011
|
| DOI | 10.1007/s00259-011-1902-1 |
| Pubmed ID | |
| Authors |
Lisa Bodei, Marta Cremonesi, Chiara M. Grana, Nicola Fazio, Simona Iodice, Silvia M. Baio, Mirco Bartolomei, Dario Lombardo, Mahila E. Ferrari, Maddalena Sansovini, Marco Chinol, Giovanni Paganelli |
| Abstract |
Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2 somatostatin receptors (sst(2)), mainly neuroendocrine. The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of (177)Lu-DOTATATE in multiple cycles. Fifty-one consecutive patients with unresectable/metastatic sst(2)-positive tumours, divided into two groups, received escalating activities (3.7-5.18 GBq/cycle, group 1; 5.18-7.4 GBq/cycle, group 2) of (177)Lu-DOTATATE. Cumulative activities ranged from 3.7 to 29.2 GBq (median 26.4 GBq in median 6 cycles, group 1, 21 patients) and 5.55 to 28.9 GBq (median 25.2 GBq in 4 cycles, group 2, 30 patients), based on dosimetry. No major acute or delayed renal or haematological toxicity occurred (one grade 3 leukopenia and thrombocytopenia). Cumulative renal absorbed doses were 8-37 Gy (9-41 Gy bioeffective doses). A median decrease of creatinine clearance of 21.7% 6 months after PRRT, 23.9% after 1 year and 27.6% after 2 years was observed. Higher losses (>20%) occurred in patients with risk factors for renal toxicity, particularly hypertension and diabetes. Cumulative bone marrow doses were <1.5 Gy. Blood elements showed a progressive mild drop during cycles and recovered during follow-up (median 30 months). Thirty-nine patients were progressive at enrolment. Partial and complete responses occurred in 15 of 46 (32.6%) assessable patients. The median time to progression was 36 months. Overall survival was 68% at 36 months. Non-responders and patients with extensive tumour involvement had lower survival. (177)Lu-DOTATATE was well tolerated up to 29 GBq cumulative activity (up to 7.4 GBq/cycle). The maximum tolerated dose/cycle was not reached. However, considering the individual bone marrow function and the presence of risk factors for kidney toxicity, it seems safer to divide cumulative activities into lower activity cycles. |
Mendeley readers
The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Italy | 1 | <1% |
| Unknown | 162 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 18% |
| Other | 19 | 12% |
| Student > Master | 18 | 11% |
| Student > Ph. D. Student | 17 | 10% |
| Student > Bachelor | 14 | 8% |
| Other | 32 | 19% |
| Unknown | 35 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 65 | 39% |
| Physics and Astronomy | 16 | 10% |
| Chemistry | 10 | 6% |
| Agricultural and Biological Sciences | 7 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Other | 16 | 10% |
| Unknown | 45 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2018.
All research outputs
#1,795,829
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#98
of 3,083 outputs
Outputs of similar age
#8,477
of 127,027 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#1
of 17 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 127,027 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.